Industry News

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced the appointment of Kirk Malloy, Ph.D. to the company’ s Board of Directors, effective September 12, 2016. The Board now consists of seven members.. Malloy is a senior healthcare executive with more than 20 years of leadership in life science tools, applied markets and molecular diagnostics."/>
NanoString Technologies Appoints Kirk Malloy, Ph.D. to Board of Directors
Photocure ASA: Share capital increase registered
EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. under the Company's License Agreement with Valeant, pursuant to which EyeGate has granted Valeant exclusive, worldwide commercial and..."/>
EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
InMed Pharmaceuticals, Inc., a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, today announced that Andrew Hull has been appointed to the Board of Directors, effective September 12, 2016.. Hull's career has spanned over thirty years as a corporate executive in the global healthcare and biotechnology industries, including the last fourteen years at Takeda..."/>
InMed Appoints Andrew Hull to the Board of Directors
EyeGate Pharmaceuticals, Inc., a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. under the Company's License Agreement with Valeant, pursuant to which EyeGate has granted Valeant exclusive, worldwide commercial and..."/>
EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
Oneview Healthcare PLC today announced the appointment of internationally recognized healthcare IT and innovation specialists, Dr. Lyle Berkowitz to its Global Leadership Team to further grow and develop the company's next generation technology for patient engagement. Bokser, of the University of California San Francisco, has been appointed Chief Medical Officer and Chairman of Oneview's International Advisory Board; and Dr."/>
Oneview Healthcare Attracts U.S. Medical Talent to Global Leadership Team
Karolinska Development AB today announces that its portfolio company Promimic AB, an innovative biomaterials company, has secured SEK 23.8 million in a new share issue to finance the establishment of its commercial operations in the US, the world's largest market for medical implants. Chalmers Ventures, one of Sweden's most prolific investors in innovative businesses, participated as a new investor alongside existing investors KDev Investments..."/>
Karolinska Development portfolio company Promimic AB raises SEK 23.8 million to establish commercial operations in the US
Bavarian Nordic A/S today announced its financial calendar for the year 2017.. Pursuant to Article 12 of the Articles of Association, shareholders who wish to submit a request for proposals for consideration at the Annual General Meeting must lodge this with the Company no later than Wednesday, March 15, 2017.. Moreover, it should be noted that Bavarian Nordic in a period of two weeks before planned publication of quarterly reports, will..."/>
Bavarian Nordic Issues Financial Calendar for 2017
Starpharma Holdings Ltd today announced it had been granted a medical device license for the VivaGel ® condom by the Canadian regulatory authority, Health Canada. Starpharma’ s marketing partner, Ansell, plans to launch the VivaGel ® condom in Canada as soon as possible under the LifeStyles ® Dual Protect™ brand. The VivaGel ® condom is a world-first product based on innovative Australian technology."/>
Starpharma: VivaGel® Condom Receives Regulatory Approval in Canada
Aetna Inc. says that "marketplace reality" is pushing the company to exit many public health care exchanges and dismissed criticism of the company by a group of U.S. senators as "unfounded accusations." Aetna CEO Mark Bertolini wrote to the senators who said Aetna was seeking to stem financial losses when it announced it will quit nearly 70 percent of the counties with public health exchanges next year. Bertolini was responding to a letter..."/>
Aetna CEO Responds To Senators' Accusations [The Hartford Courant]
NanoViricides, Inc., a global leader in nanomedicines that is developing biomimetic anti-viral drugs announced that it will be featured as a presenting company today at the 18th Annual Rodman& Renshaw Global Investment Conference, sponsored by H.C. The conference is being held on September 11-13, 2016, at Lotte New York Palace Hotel in New York City. Eugene Seymour, MD, MPH, CEO of NanoViricides, will provide an overview of the Company's..."/>
NanoViricides to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City Today
Humana and Dr. Stacy L. Smith at the USC Annenberg School for Communication and Journalism reveal prevalence of ageism in film and the power of embracing a healthy mindset for healthy aging. LOUISVILLE, Ky.---- New research reveals few characters aged 60 and over are represented in film, and that prominent senior characters face demeaning or ageist references."/>
Film Study: Pop Culture Stereotypes Aging Americans
RespireRx Pharmaceuticals Inc. is a leader in the development of medicines for respiratory disorders, including drug-induced respiratory depression and sleep apneas. RespireRx is today reporting preliminary top-line data from its Phase 2 A clinical trial of CX1739, the Company's proprietary, orally administered ampakine. CX1739 was determined to be safe and well tolerated, and antagonized the respiratory depressive effects of remifentanil, a..."/>
UPDATE - RespireRx Pharmaceuticals Inc. Announces Preliminary Top-Line Analysis of Data From Duke University Phase 2A Clinical Trial of CX1739
Arch Therapeutics, Inc., developer of AC5™ devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, was featured as a presenting company today at the 18th Annual Rodman& Renshaw Global Investment Conference taking place at the Lotte New York Palace Hotel in New York City. Terrence W. Norchi, MD, CEO, accompanied by Richard Davis, CFO, provided a corporate update, which included discussion of..."/>
Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference
PRA Health Sciences unveiled a strategic partnership with Japanese drug giant Takeda Pharmaceutical that includes transferring about 300 employees around the globe to the Raleigh-based pharmaceutical services company. None of the new employees, however, will work in the Triangle, where PRA employs about 500 workers. Although financial details weren't disclosed, analyst Tim Evans of Wells Fargo Equity Research estimated that, based on Takeda's $3.4 billion..."/>
PRA forms partnership with giant Japanese drug company [The News & Observer (Raleigh, N.C.)]
Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs in rare diseases, today announced that it will participate in a fireside chat at the 2016 Morgan Stanley Global Healthcare Conference on September 14, 2016. Chief Executive Officer Jan Mikkelsen and Chief Financial Officer Scott T. Smith will attend. A live audio webcast of the event will..."/>
Ascendis Pharma A/S Announces Participation in 2016 Morgan Stanley Global Healthcare Conference on September 14
BIOLASE Laser Therapy vs. Traditional Techniques in Management of Periodontal Disease. IRVINE, Calif.---- BIOLASE, Inc., the global leader in dental lasers, announced at the 102 nd session of the American Academy of Periodontology in San Diego, Calif., that it has entered into a clinical research agreement with The McGuire Institute, a leading practice-based dental research organization specializing in evidence-based research to advance the..."/>
BIOLASE Enters into Clinical Research Agreement with McGuire Institute for Landmark Laser Perio Research Project

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology554 Articles
Consumer Discretionary488 Articles
Financials317 Articles
Industrials312 Articles
Health Care278 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.